Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1246196 | 0.98 | CHRM2 (0.44) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| Trifluoroacetic Acid SCHEMBL6523373 | 0.97 | CHRM2 (0.42) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL12788933 | 0.96 | CHRM2 (0.44) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL12846730 | 0.96 | CHRM3 (0.44) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL14616984 | 0.95 | CHRM3 (0.45) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL12788946 | 0.94 | CHRM2 (0.47) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| Trifluoroacetic Acid SCHEMBL6522142 | 0.93 | CHRM3 (0.41) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL12789034 | 0.93 | CHRM3 (0.45) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL12788923 | 0.92 | CHRM3 (0.45) | CHRM2CHRM3ADRB2SMYD2DRD2 | |
| SCHEMBL6527432 | 0.92 | CHRM2 (0.41) | CHRM2CHRM3ADRB2SMYD2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | claimed |
| WO-2012085583-A1 | NEW COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2012085583-A1 | NEW COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085583-A1 | NEW COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085583-A1 | NEW COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM2 910/4885CHRM3 167/4885ADRB2 147/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM2 910/4885CHRM3 167/4885ADRB2 147/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM2 910/4885CHRM3 167/4885ADRB2 147/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM2 910/4885CHRM3 167/4885ADRB2 147/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM2 910/4885CHRM3 167/4885ADRB2 147/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CHRM2 157/4885CHRM3 97/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.